InSysBio to take part in ESMO Congress 2021

events
Conference
July 28, 2021

July 28, 2021

InSysBio announces its participation in ESMO (European Sosiety For Medical Oncology) Virtual Congress 2021 which is held on September 16-21. InSysBio team’s abstract was accepted:

  • #3143 “Selection of the optimal dose for ALX148, a CD47 blocker, using pharmacokinetic/pharmacodynamic modeling” by Elena Vasileva1,2, Oleg Demin Jr2

Affiliation: 1 Lomonosov Moscow State University, Moscow, Russia; 2InSysBio, Moscow, Russia

Abstract is going to be published on September 13, 2021, 00:05 CEST (Central European Summer Time)

About InSysBio

InSysBio is a Quantitative Systems Pharmacology (QSP) company located in Moscow, Russia (INSYSBIO LLC) and Edinburgh, UK (INSYSBIO UK LIMITED). InSysBio was founded in 2004 and has an extensive track record of helping pharmaceutical companies to make right decisions on the critical stages of drug research and development by application of QSP modeling. InSysBio’s innovative QSP approach has already become a part of the drug development process implemented by our strategic partners: there are more than 120 completed projects in collaboration with leaders of pharmaceutical industry. For more information about InSysBio, its solutions and services, visit www.insysbio.com.

July 2017
MoTuWeThFrSaSu
     
1
2
3
4
5
6
7
8
9
10
11
12
13
14
1. 14 Jul 2017 18:49 To predict unpredictable: a platform for modeling of the high-selective oncology drugs was created Moscow, Russia, July 14, 2017. The scientists from BIND RUS and InSysBio (www.insysbio.ru) published a joint research of the new class of anti-oncology treatment in the Journal of Controlled Release. Unique nanoparticles enriched with medications can deliver its content targeted to the tumor site, and the parameters of their effectiveness are programmed during the forming phase.
15
16
17
18
19
20
21
22
23
24
25
1. 25 Jul 2017 13:50 InSysBio LLC Announce Renewal of Agreement with ASTEX Pharmaceuticals Inc. Moscow, Russia, July 25, 2017 – InSysBio LLC (www.insysbio.ru), one of the pioneers in Quantitative Systems Pharmacology (QSP) modeling and simulation for drug development, announced today a renewal of multi-year Master Service Agreement with ASTEX Pharmaceuticals, Inc.
2. 25 Jul 2017 17:37 InSysBio will present at the American Conference on Pharmacometrics (ACoP8)! Moscow, Russia, July 26, 2017. - Event announcement. This year the scientific team of InSysBio will make 9 poster presentations in conjunction with leading pharmaceutical companies at ACoP8. Also at the special session "QSP Modular design - Approaches to speed up the QSP model development" Oleg Demin Jr will hold a workshop on modeling with the Immune Response Template (IRT) platform.
26
27
28
29
30
31
      
Upcoming Events
07.04
InSysBio to hold a workshop on Heta at QSPC 2026
08.04
InSysBio to participate in QSPC 2026
Tags
Latest News
28.01
InSysBio to announce a new collaborative project with BeOne Medicines
29.10
InSysBio to announce its collaboration with BeOne Medicines
16.10
InSysBio to introduce a new data annotation service available in CYTOCON DB and fIVE DB
19.08
InSysBio to publish the new article "Revolutionizing drug discovery: Integrating artificial intelligence with quantitative systems pharmacology"
05.08
InSysBio to launch Immune Response Template Open for QSP modeling